NICE rejects Roche's Tecentriq in new lung cancer use

NICE has said in first draft guidance that Roche’s Tecentriq should not get regular NHS funding as a treatment for a kind of advanced lung cancer, citing “highly uncertain” data about the d

AZ's Imfinzi approved in early lung cancer in China

The Chinese regulator has approved AstraZeneca’s Imfinzi in an early form of lung cancer after treatment with chemotherapy and radiation.

FDA grants AZ's Imfinzi fast review in new lung cancer use

The FDA has granted AstraZeneca’s Imfinzi immunotherapy a faster six-month review in patients with extensive-stage small cell lung cancer.

Merck KGaA nabs FDA "Breakthrough" tag for MET-targeting lun...

The FDA thinks German Merck could have a breakthrough in its hands with a new lung cancer drug that targets aggressive tumours with a mutation known as MET.

Relief for Lilly as drug from $8bn Loxo deal clears pivotal ...

Mixed reviews for Amgen's KRAS drug after lung cancer data r...

Eagerly awaited trial data from Amgen’s latest KRAS-targeting cancer drug AMG 510 emerged over the weekend – and the results have received broadly positive reviews.